Signature STb O — The monitoring-ready baseline.
118 genes. A simple blood draw. The gateway to continuous monitoring.
Signature STb O widens the lens to 118 genes from the same simple blood draw. It is the balanced middle tier: broad enough to capture the great majority of clinically-relevant alterations and the immune-related markers, and — crucially — broad enough to serve as the molecular baseline for continuous Sentinel monitoring.
The balanced middle tier
Broad enough for reliable TMB and copy-number read, and the fingerprint that Sentinel draws are compared against.
- 118 genes: Actionable drivers, fusions, and immune markers
- Sentinel gateway: Establishes the baseline for continuous monitoring
- Full immune profile: TMB, MSI and MMR — analytically robust
- PGx panel: 35-gene pharmacogenomics & drug-response profile
- Blueprint Care: Ranked decision, signed by KPCIRC
The sweet spot for most solid tumours.
118 genes is the natural choice when you want more than urgent triage but do not yet need the fullest comprehensive profile.
Covers Actionable Drivers
Captures the great majority of clinically-relevant alterations and fusions across solid tumours.
Reliable TMB & CNV Read
Broad enough for a reliable Tumour Mutational Burden and copy-number read — essential for immunotherapy and treatment planning.
Sentinel Baseline
Establishes the molecular fingerprint that later Sentinel draws are compared against. A 33-gene panel is too narrow for this.
Complete. Balanced. Monitoring-ready.
Everything you need for a broad baseline — with the immune and PGx profile baked in.
SNVs, InDels & Fusions
Across 118 genes — capturing the great majority of clinically-relevant alterations and fusions.
Full Immune Profile
TMB, MSI and MMR — the full set, analytically robust at this breadth.
Copy-Number & Mutational Signatures
Analytically robust at 118 genes, supporting broader treatment and trial matching.
Pharmacogenomics (PGx)
The 35-gene panel — how you may metabolise and react to key cancer drugs.
Tumour-Fraction Estimate
How much tumour DNA was present — so results are read in context.
TMB (Tumour Mutational Burden) counts how many mutations a tumour carries. A high count often means the immune system can recognise it — a signal that immunotherapy may help. A reliable TMB needs a broad panel of genes to measure accurately.
MSI (Microsatellite Instability) and MMR (Mismatch-Repair status) describe whether the tumour's DNA-proofreading machinery is broken. When it is (MSI-high / deficient MMR), the tumour accumulates mutations and frequently responds well to immunotherapy.
This is the baseline Sentinel needs.
Continuous monitoring only works if there is a molecular fingerprint to track. Signature STb O establishes that fingerprint.
Once you have Signature STb O, Sentinel (Track) can follow your cancer over time on the same 118-gene breadth — watching treatment work and flagging resistance early.
A 33-gene panel is too narrow to serve as this baseline. The 118-gene breadth gives Sentinel the robust fingerprint it needs to detect meaningful changes in your cancer's molecular profile.
Sentinel Continuous Monitoring
Serial blood tests track your cancer in real-time — catching resistance or recurrence months before a scan would.
Requires a 118-gene baselineFrom result to action plan.
The 118-gene result flows into Blueprint Care: a ranked decision, contraindications, trial matches, biosimilar options, resistance and monitoring plan, and access pathway — all signed by KPCIRC.
Is Signature STb O right for you?
Two clear reasons to choose the 118-gene baseline.
You want a broad, monitoring-ready profile
You need more than urgent triage (33 genes) but do not yet need the fullest comprehensive profile (CGP). 118 genes gives you the breadth for confident treatment decisions and immune profiling.
You anticipate ongoing surveillance
You want to establish a Sentinel baseline now — so you can track your cancer over time and catch resistance early. This is the gateway to continuous monitoring.
Confirmed at your consultation.
Pricing for Signature STb O is confirmed at your free consultation, alongside whether the tier fits your goals.
The words you will see, in plain language.
What we DO
- Profile 118 genes with a full immune & PGx profile
- Establish the molecular baseline Sentinel needs
- Feed a complete, MTB-signed Blueprint Care decision
- Support copy-number and mutational-signature analysis
What we DON'T do
- Diagnose or decide treatment on its own
- Rule out disease from a negative result
- Cover every gene in the genome
- Guarantee drug availability, approval, cover, or benefit
Signature STb O is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →